Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
Por:
Blauvelt, A, Papp, KA, Griffiths, CEM, Puig, L, Weisman, J, Dutronc, Y, Kerr, LF, Ilo, D, Mallbris, L, Augustin, M
Publicada:
1 jun 2018
Resumen:
The article Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) written by Andrew Blauvelt.
Filiaciones:
Blauvelt, A:
Oregon Med Res Ctr, 9495 SW Locust St,Suite G, Portland, OR 97223 USA
Papp, KA:
K Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
Griffiths, CEM:
Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Weisman, J:
Med Dermatol Specialists Inc, Atlanta, GA USA
Dutronc, Y:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Kerr, LF:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Ilo, D:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Mallbris, L:
Eli Lilly & Co, Indianapolis, IN 46285 USA
Augustin, M:
Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
Green Published
|